Clinical Trial Update: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) [Phase 1]

View source ↗

Summary

Phase 1 study of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors has completed, reporting initial safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MK-0482
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms | Phase 1 | Status: COMPLETED